BioAge Labs to Present at Upcoming Investor Conferences
BioAge Labs to Present at Upcoming Investor Conferences
RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
加利福尼亚州里士满，2024年11月21日（GLOBE NEWSWIRE）——临床阶段的生物制药公司BioAge Labs（纳斯达克股票代码：BIOA）（“BioAge”，“公司”）今天宣布，该公司将参加以下即将举行的投资者会议：
- Piper Sandler 36th Annual Healthcare Conference (New York, December 3-5, 2024): Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a company presentation on December 3, 2024 from 1:30 PM to 1:55 PM EST, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
- Citi 2024 Global Healthcare Conference (Miami, December 3-5, 2024): Kristen Fortney, CEO and co-founder, PhD, is scheduled to participate in a company presentation on December 4, 2024 from 3:15 PM to 3:55 PM EST, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
- 派珀·桑德勒第36届年度医疗保健会议（纽约，2024年12月3日至5日）：首席执行官兼联合创始人克里斯汀·福特尼博士计划于美国东部时间2024年12月3日下午 1:30 至下午 1:55 参加公司演讲，并将参加一对一的会议。要观看演示文稿的网络直播，请注册 这里.
- 花旗2024年全球医疗保健大会（迈阿密，2024年12月3日至5日）：首席执行官兼联合创始人克里斯汀·福特尼博士计划于美国东部时间2024年12月4日下午3点15分至3点55分参加公司演讲，并将参加一对一的会议。要观看演示文稿的网络直播，请注册 这里.
Replays of the webcasts will be available in the investor section of the company's website at , and will be archived for 30 days following the presentations.
网络直播的重播将在公司网站的投资者专区播出，网址为 ，并将在演讲结束后存档 30 天。
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge's lead product candidate, azelaprag, is an orally available small molecule agonist of APJ that was observed to promote metabolism and prevent muscle atrophy on bed rest in a Phase 1b clinical trial. In mid-2024, BioAge initiated a Phase 2 trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. BioAge's preclinical programs, based on novel insights from the company's discovery platform built on human longevity data, address key pathways in metabolic aging.
关于 BioAge Labs, Inc.
BioAge是一家临床阶段的生物制药公司，通过针对人类衰老的生物学，开发肥胖等代谢性疾病的候选治疗产品。BioAge的主要候选产品azelaprag是APJ的一种口服小分子激动剂，在一项10期临床试验中被观察到可促进新陈代谢并防止卧床休息时肌肉萎缩。2024年中期，BioAge启动了阿泽拉普拉格与替塞帕肽联合治疗老年人肥胖症的2期试验。Azelaprag有可能作为一种口服疗法，在使用肠促素药物进行肥胖治疗的患者的体重减轻和改善身体成分。BioAge还在开发口服的小分子脑穿透剂 NLRP3 抑制剂，用于治疗由神经炎症引起的疾病。BioAge的临床前项目基于该公司基于人类寿命数据的发现平台的新见解，旨在解决代谢衰老的关键路径。
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Elena Liapounova, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web:
联系人
公关：克里斯·帕蒂尔，media@bioagelabs.com
投资者关系：Elena Liapounova，ir@bioagelabs.com
合作：partnering@bioagelabs.com
网页：
